黄连生物碱治疗糖尿病——解偶联蛋白2

On a New Target for Treating Diabetes by Alkaloids of Rhizoma Coptis-UCP2

用不同浓度(4.00,2.00,1.00,0.50和0.25mg/L)的黄连生物碱(黄连碱、小檗碱、表小檗碱、巴马汀)处理肝癌细胞(HepG2),应用HPLC和蛋白质印迹技术检测黄连生物碱在HepG2细胞中的吸收及黄连生物碱对解偶联蛋白2(UCP2)表达的影响.同一浓度下,HepG2细胞内黄连碱的浓度最高,小檗碱次之,其余生物碱含量较低;UCP2的表达量,黄连碱组最高、小檗碱次之,且随着黄连碱浓度和表小檗碱浓度的不断增加,细胞内UCP2相对表达量也增加,其它两组对UCP2表达影响不明显.黄连碱与小檗碱可以促进线粒体UCP2的表达且与治疗糖尿病并发症相关联.

To investigate the absorption of the alkaloids from rhizoma Coptis by HepG2 cells and the effect of alkaloids on the expression of uncoupling protein 2 （UCP2）, the cell has been divided into 5 groups. control group, coptisine group, berberine group, epiberberine group and palmatine group, Each group contains different concentrations as follows： 4.00,2.00,1.00,0.50,0.25 mg/L. After 24 hours drug administration, the concentration of drug intracellular and the expression of UCP2 have been detected by HPLC and western blot, respectively. In the same drug dose, the concentration of intracellular coptisine is the highest, followed by berberine, others are the lowest, and so is the expression of UCP2. The expression of UCP2 can be promoted by coptisine and berberine, which is associated with the treatment of diabetes complications.